Boxer Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.02M Buy
944,035
+195,000
+26% +$1.03M 0.44% 30
2026
Q2
$3.63M Hold
749,035
– – 0.27% 46
2026
Q1
$2.56M Buy
+749,035
New +$1.55M 0.34% 41

Other funds holding ANTX

Boxer Capital Management's ANTX Position: Q3 2026 in Review

Boxer Capital Management increased its AN2 Therapeutics (ANTX) stake by 26% in Q3 2026, buying an estimated $1.03M and bringing the position to 944,035 shares worth $5.02M. The position accounts for 0.44% of the portfolio, ranked #30.

Boxer Capital Management first reported a position in ANTX in Q1 2026 and has held it in 3 quarters since. 88 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Boxer Capital Management held 944,035 shares of AN2 Therapeutics worth $5.02M as of Q3 2026.
  • Boxer Capital Management bought 195,000 AN2 Therapeutics shares in Q3 2026, an estimated $1.03M.
  • AN2 Therapeutics made up 0.44% of Boxer Capital Management's portfolio in Q3 2026, its #30 holding.
  • Boxer Capital Management first reported a position in AN2 Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 88 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.